See more : HORAI Co., Ltd. (9679.T) Income Statement Analysis – Financial Results
Complete financial analysis of Eiger BioPharmaceuticals, Inc. (EIGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eiger BioPharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MSTC Limited (MSTCLTD.NS) Income Statement Analysis – Financial Results
- B. Riley Financial, Inc. (RILYP) Income Statement Analysis – Financial Results
- flyExclusive, Inc. (FLYX) Income Statement Analysis – Financial Results
- Mishra Dhatu Nigam Limited (MIDHANI.NS) Income Statement Analysis – Financial Results
- Galexxy Holdings, Inc. (GXXY) Income Statement Analysis – Financial Results
Eiger BioPharmaceuticals, Inc. (EIGR)
About Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.77M | 13.48M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.00K | 1.84M | 745.00K | 645.00K | 486.00K | 54.00K | 41.00K | 23.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 15.75M | 11.65M | 11.40M | -645.00K | -486.00K | -54.00K | -41.00K | -23.00K | -11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 99.85% | 86.38% | 93.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.33M | 75.28M | 64.44M | 41.59M | 51.79M | 37.09M | 29.52M | 33.01M | 21.96M | 22.68M | 16.93M | 13.31M | 4.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.20M | 29.11M | 23.90M | 20.56M | 17.11M | 13.96M | 12.00M | 13.11M | 12.44M | 10.34M | 3.04M | 2.63M | 1.83M |
| Other Expenses | 87.00K | -963.00K | 46.49M | -12.00K | -15.00K | -12.00K | 186.00K | -277.00K | 5.00K | -835.00K | 25.00K | 147.00K | 152.00K |
| Operating Expenses | 87.54M | 104.39M | 88.34M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Cost & Expenses | 87.56M | 106.22M | 89.08M | 62.15M | 68.90M | 51.05M | 41.52M | 46.12M | 34.39M | 33.02M | 19.96M | 15.95M | 6.03M |
| Interest Income | 2.21M | 1.08M | 158.00K | 704.00K | 2.07M | 997.00K | 410.00K | 0.00 | 65.00K | 118.00K | 69.00K | 35.00K | 7.00K |
| Interest Expense | 5.47M | 4.13M | 3.56M | 3.59M | 3.41M | 2.33M | 1.52M | 690.00K | 2.30M | 741.00K | 59.00K | 108.00K | 1.12M |
| Depreciation & Amortization | 750.00K | 119.00K | 46.65M | 1.34M | 2.54M | 54.00K | 41.00K | 23.00K | 504.00K | 153.00K | 67.00K | 64.00K | 73.00K |
| EBITDA | -68.74M | -92.62M | -76.94M | -60.81M | -66.36M | -50.06M | -40.92M | -46.40M | -33.82M | -33.02M | -19.80M | -15.70M | -5.79M |
| EBITDA Ratio | -435.81% | -686.90% | -249.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.79M | -92.74M | -76.94M | -62.15M | -68.90M | -51.05M | -41.52M | -46.12M | -42.18M | -33.02M | -19.96M | -15.95M | -6.03M |
| Operating Income Ratio | -455.12% | -687.78% | -633.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.17M | -4.01M | 43.09M | -2.90M | -1.35M | -1.34M | -928.00K | -967.00K | -2.23M | -835.00K | -127.00K | 74.00K | -965.00K |
| Income Before Tax | -74.96M | -96.75M | -33.85M | -65.05M | -70.25M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.09M | -15.87M | -6.99M |
| Income Before Tax Ratio | -475.22% | -717.54% | -278.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 6.00K | 23.00K | 64.00K | 3.58M | 3.39M | 985.00K | 1.67M | 390.00K | 2.31M | -153.00K | -12.00K | 101.00K | 1.28M |
| Net Income | -74.96M | -96.78M | -33.92M | -68.63M | -73.64M | -52.39M | -42.45M | -47.09M | -44.41M | -33.85M | -20.00M | -15.72M | -6.99M |
| Net Income Ratio | -475.26% | -717.71% | -279.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| EPS Diluted | -50.78 | -69.74 | -0.98 | -2.30 | -3.01 | -3.84 | -4.86 | -5.63 | -35.11 | -21.62 | -24.92 | -19.59 | -8.71 |
| Weighted Avg Shares Out | 1.48M | 1.39M | 34.63M | 29.88M | 24.43M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
| Weighted Avg Shares Out (Dil) | 1.48M | 1.39M | 34.63M | 29.88M | 24.50M | 13.63M | 8.73M | 8.36M | 1.27M | 1.57M | 802.36K | 802.36K | 802.36K |
Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst
European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by...
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs",...
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call Transcript
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - President & Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development...
Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon
A near-term opportunity in hepatitis D virus (HDV) infection with lead asset lonafarnib supports valuation 6x higher than current share price, supported by a recent acquisition in the HDV space.
Why Eiger BioPharmaceuticals Stock Is Jumping Today
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness. Peginterferon Lambda significantly reduced the risk of COVID-19-related.
Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022
Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis...
How Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%
The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q4 2021 Results - Earnings Call Transcript
Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q4 2021 Results - Earnings Call Transcript
Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory,...
Source: https://incomestatements.info
Category: Stock Reports